Youngevity CEO Steve Wallach to Speak on Multimillion-Dollar Cannabidiol Direct-Selling Market at Upcoming CBD Symposium
YGYI, Inc. (NASDAQ:YGYI) (“Youngevity,” “YGYI” or “the Company”), a leading omni-direct lifestyle company specializing in a hybrid of the direct-selling business model, announces its participation in the upcoming CBD Symposium, hosted by SUCCESS Partners and Direct Selling News. Youngevity CEO Steve Wallach will be a featured speaker at this premier cannabidiol (CBD) industry-focused event, which will take place Nov. 6, 2018, in Dallas, Texas.
It has been estimated that direct-selling companies will sell $300 million in CBD-related products in 2018, which would make direct-selling the largest distribution channel for this rapidly growing product sector. Youngevity has assembled a veritable Main Street of products and services under one corporate umbrella, uniting e-commerce and the power of social selling to offer these products through one effective direct-selling hybrid, and believes it is well-positioned to capitalize on the expected CBD direct-selling boom.
“We are pleased to participate in the upcoming CBD Symposium. Unquestionably, CBD has become the hottest topic in the direct-selling channel, and this event presents a prime opportunity for sharing information about CBD and how best to utilize the direct-selling business model in offering this transformative product to the public,” said Youngevity CEO Steve Wallach, who serves on the board of directors of the Direct Selling Association (DSA). “As the CEO of a company that has successfully transitioned from a domestic seller to a global marketer of products and services that support a healthy and empowered lifestyle, it is a privilege to be among the experts invited to speak at this symposium.”
Among Youngevity’s product offerings, which target the eight top-selling retail categories, the Company recently launched Hemp FX™, a line of hemp-derived CBD products that are available for purchase through the fully transactional website www.hempfx.com. This product line currently includes three proprietary formulas that feature Youngevity’s hemp-derived, phytocannabinoid-rich, full-spectrum, organically grown CBD oil, and two tablet-based CBD products in the HempFX™ Hydration™ category. The tablet-based products will be used with Youngevity’s Y-DR8+ proprietary, portable water bottle system designed to help provide great tasting water and reduce chemicals found in tap water. The Y-DR8 filter features (ACC) activated carbon cloth and is portable to fit today’s “On the go lifestyle”.
Ticket information for the CBD Symposium can be found here.
About Youngevity International, Inc.
YGYI, Inc. (NASDAQ:YGYI), is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model, that also offers e-commerce and the power of social selling. Assembling a virtual Main Street of products and services under one corporate entity, YGYI offers products from the eight top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, fashion, essential oils, photo, as well as innovative services. The Company was formed in the course of the summer 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company (now part of the company’s food and beverage division). The resulting company became Youngevity International, Inc. in July 2013. For investor information, please visit YGYI.com. Be sure to like us on Facebook and follow us on Twitter.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and includes statements regarding direct-selling companies selling $300 million in CBD-related products in 2018, our being well-positioned to capitalize on the expected CBD direct-selling boom, and our introduction of additional CBD products in the near future.. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of direct-selling companies to sell $300 million in CBD-related products in 2018, our ability to capitalize on the expected CBD direct-selling boom, our ability to introduce additional CBD products in the near future, our ability to continue our international growth, our ability to leverage our platform and global infrastructure to drive organic growth, our ability to improve our profitability, expand our liquidity, and strengthen our balance sheet, our ability to continue to maintain compliance with the NASDAQ requirements, the acceptance of the omni-direct approach by our customers, our ability to expand our distribution, our ability to add additional products (whether developed internally or through acquisitions), our ability to continue our financial performance, and the other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017 and our subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.